Abstract
Chromium is generally believed to be an essential trace element and to have a role in maintaining proper carbohydrate and lipid metabolism, probably by enhancing insulin signaling. Three recent events have strongly influenced biochemical and nutritional studies of Cr(III): (1) the Food and Nutrition Board’ new daily adequate intake (AI) of Cr, (2) the Food Standards Agency’s determination that Cr picolinate might have the potential to cause cancer, and (3) the National Institutes of Health’s program announcement “Chromium as an adjuvant therapy for type 2 diabetes and impaired glucose tolerance.” A discussion of these three events allows the current understanding of the nutritional biochemistry of Cr to be outlined.
Similar content being viewed by others
References
Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. A Report of the Panel on Micronutrients, Subcommittee on Upper Reference Levels of Nutrients and of Interpretations and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, National Academy of Sciences, Washington, DC (2002).
P. Trumbo, A. A. Yates, S. Schlicker, et al., Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc, J. Am. Diet. Assoc. 101, 294–301 (2001).
Recommended Daily Allowances, 9th ed., Report of the Committee on Dietary Allowances, Division of Biological Sciences, Assembly of Life Science, Food and Nutrition Board, National Academy Press, Washington, DC (1980).
Recommended Daily Allowances, 10th ed., Subcommittee on the Tenth Edition of the RDAs, Food and Nutrition Board Commission on Life Sciences, National Research Council, National Academy Press, Washington, DC (1989).
R. A. Anderson, N. A. Bryden, and M. M. Polansky, Dietary chromium intake. Freely chosen diets, institutional diets, and individual foods, Biol. Trace Element Res. 32, 117–121 (1992).
R. A. Anderson and A. S. Kozlovsky, Chromium intake, absorption and excretion of subjects consuming self-selected diets, Am. J. Clin. Nutr. 41, 1177–1183 (1985).
R. S. Gibson and C. A. Scythes, Chromium, selenium, and other trace element intakes of a selected sample of Canadian premenopausal women, Biol. Trace Element Res. 6, 105–116 (1984).
E. G. Offenbacher, H. Spencer, H. J. Dowling, et al., Metabolic chromium balances in men, Am. J. Clin. Nutr. 44, 77–82 (1986).
V. W. Bunker, M. S. Lawson, H. T. Delues, et al., The uptake and excretion of chromium by the elderly, Am. J. Clin. Nutr. 39, 797–802 (1984).
K. N. Jeejeebhoy, The role of chromium in nutrition and therapeutics and as a potential toxin, Nutr. Rev. 57, 329–335 (1999).
D. M. Stearns, Is chromium a trace essential metal? Biofactors 11, 149–162 (2000).
J. B. Vincent, The potential value and potential toxicity of chromium picolinate as a nutritional supplement, weight loss agent, and muscle development agent, Sports Med. 33, 213–230 (2003).
P. M. Clarkson, Effects of exercise on chromium levels: is supplementation required? Sports Med. 23, 341–349 (1997).
R. B. Kreider, Dietary supplements and the promotion of muscle growth with resistance exercise, Sports Med. 27, 97–110 (1999).
H. C. Lukaski, Chromium as a supplement, Annu. Rev. Nutr. 19, 279–301 (1999).
M. H. Pittler, C. Stevinson, and E. Ernst, Chromium picolinate for reducing body weight: meta-analysis of randomized trials, Int. J. Obes. 27, 522–529 (2003).
S. L. Nissen and R. L. Sharp, Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis, J. Appl. Physiol. 94, 651–659 (2003).
J. B. Vincent, The bioinorganic chemistry of chromium(III), Polyhedron 20, 1–26 (2001).
M. D. Althius, N. E. Jordan, E. A. Ludington, et al., Glucose and insulin responses to dietary chromium supplements: a meta-analysis, Am. J. Clin. Nutr. 76, 148–155 (2002).
New Advice on Safety of High Doses of Vitamins and Minerals. Available from www.foodstandards.gov.uk/news/newsarchive/safetyhighdosesvitsandmins (accessed 08 May 2003).
G. W. Evans, The effect of chromium picolinate on insulin controlled parameters in humans, Int. J. Biosoc. Med. Res. 11, 163–180 (1989).
D. M. Stearns, J. P. Wise, Sr., S. R. Patierno, et al., Chromium(III) picolinate produces chromosome damage in Chinese hamster ovary cells, FASEB J. 9, 1643–1648 (1995).
D. Bagchi, M. Bagchi, J. Balmoori, et al., Comparative induction of oxidative stress in cultured J774A.1 macrophage cells by chromium picolinate and chromium nicotinate, Res. Commun. Mol. Pathol. Pharmacol. 97, 335–346 (1997).
D. Bagchi, S. J. Stohs, B. W. Downs, et al., Cytotoxicity and oxidative mechanisms of different forms of chromium, Toxicology 180, 5–22 (2002).
K. R. Manygoats, M. Yazzie, and D. M. Stearns, Ultrastructural damage in chromium picolinate-treated cells: a TEM study, J. Biol. Inorg. Chem. 7, 791–798 (2002).
D. M. Stearns, S. M. Silveira, K. K. Wolf, et al., Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyl transferase locus in Chinese hamster ovary cells, Mutat. Res. 513, 135–142 (2002).
H. J. Esber, V. Moreno, and K. S. Loveday, Evaluation of chromium picolinate in the Ames and the rat in vivo chromosomal aberration assays, Mutat. Res. 379 (1 Suppl.), S89 (1997).
J. R. Komorowski and K. Loveday, Rat chromosomes are unharmed by orally administered chromium picolinate, J. Am. Coll. Nutr. 18, 527 (1999).
J. K. Speetjens, R. A. Collins, J. B. Vincent, et al., The nutritional supplement chromium(III) tris(picolinate) cleaves DNA, Chem. Res. Toxicol. 12, 483–487 (1999).
Y. Sun, J. Ramirez, S. A. Woski, et al., The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and Cr(pic)3 to LMWCr, J. Biol. Inorg. Chem. 5, 129–136 (2000).
K. D. Sugden, R. D. Geer, and S. G. Rogers, Oxygen radical-mediated DNA damage by redox-active Cr(III) complexes, Biochemistry 31, 11,626–11,631 (1992).
J. K. Speetjens, A. Parand, M. W. Crowder, et al., Low-molecular-weight chromium-binding substance and biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ do not cleave DNA under physiologically relevant conditions, Polyhedron 18, 2617–2624 (1999).
J. Cerulli, D. W. Grabe, I. Gauthier, et al., Chromium picolinate toxicity, Ann. Pharmacother. 32, 428–431 (1998).
W. G. Wasser and V. D. D’Agati, Chromic renal failure after ingestion of over-the-counter chromium picolinate, Ann. Int. Med. 126. 410 (1997).
W. R. Martin and R. E. Fuller, Suspected chromium picolinate-induced rhabdomyolysis, Pharmacotherapy 18, 860–862 (1998).
J. F. Fowler, Jr., Systemic contact dermatitis caused by oral chromium picolinate, Cutis 65, 116 (2000).
J. Huszonek, Over-the-counter chromium picolinate, Am. J. Psychiatry 150, 1560–1561 (1993).
P. C. Young, G. W. Turiansky, M. W. Bonner, et al., Acute generalized exanthematous postulosis induced by chromium picolinate, J. Am. Acad. Dermatol. 41, 820–823 (1999).
S. P. Bunner and R. McGinnis, Chromium-induced hypoglycemia, Psychosomatics 39, 298–299 (1998).
R. A. Anderson, N. A. Bryden, and M. M. Polansky, Lack of toxicity of chromium chloride and chromium picolinate in rats, J. Am. Coll. Nutr. 16, 273–279 (1997).
I. Kato, J. H. Vogelman, V. Dilman, et al., Effect of supplementation with chromium picolinate on antibody titers to 5-hydroxymethyl uracil, Eur. J. Epidemol. 14, 621–626 (1998).
D. D. D. Hepburn, J. M. Burney, S. A. Woski, et al., The nutritional supplement chromium picolinate generates oxidative DNA damage and peroxidized lipids in vivo, Polyhedron 22, 455–463 (2003).
L. Mahboob, L. McNeil, T. Tolliver, et al., Effects of chromium picolinate on antioxidant enzyme levels in rats, Toxicol. Sci. 66(1-S), 32 (2002).
D. D. D. Hepburn, J. Xiao, S. Bindom, et al., Nutritional supplement chromium picolinate causes sterility and lethal mutations in Drosophila melanogaster, Proc. Natl. Acad. Sci. USA 100, 3766–3771 (2003).
K. L. Olin, D. M. Stearns, W. H. Armstrong, et al., Comparative retention/adsorption of 51chromium (51Cr) from 51Cr chloride, 51Cr nicotinate, and 51Cr picolinate in a rat model, Trace Elements Electrolytes 11, 182–186 (1994).
Available from www.grants.nih.gov/grants/guide/pa-files/PA-01-114.html (accessed 2 July 2001).
J. B. Vincent, Elucidating a biological role for chromium at a molecular level, Acc. Chem. Res. 33, 503–510 (2000).
B. W. Morris, S. MacNeil, C. A. Hardisty, S. Heller, et al., Chromium homeostasis in patients with type II (NIDDM) diabetes, J. Trace Elements Med. Biol. 13, 57–61 (1999).
B. Morris, S. MacNeil, R. Fraser, et al., Increased urine chromium excretion in normal pregnancy, Clin. Chem. 41, 1544–1545 (1995).
R. A. Anderson, Chromium, glucose tolerance and diabetes, J. Am. Coll. Nutr. 17, 548–555 (1998).
W. H. Glinsmann and W. Mertz, Effect of trivalent chromium on glucose tolerance, Metabolism 15, 510–520 (1966).
L. Sherman, J. A. Glennon, W. J. Brech, et al., Failure of trivalent chromium to improve hyperglycemia in diabetes mellitus, Metabolism 17, 439–442 (1968).
R. Nath, J. Minocha, V. Lyall, et al., Assessment of chromium metabolism in maturityonset and juvenile diabetes using chromium-51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance, and insulin levels, in Chromium in Nutrition and Metabolism, D. Shapcott and J. Huberts, eds., Elsevier/North-Holland Biomedical, Amsterdam, pp. 213–222 (1979).
E. G. Offenbacher and F. X. Pi-Sunyer, Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects, Diabetes 29, 919–925 (1980).
A. N. Elias, K. Grossman, and L. J. Valenta, Use of artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity: effect of chromium supplementation in diabetic subjects, Gen. Pharmacol. 15, 535–539 (1984).
R. T. Mossop, Effects of chromium(III) on fasting blood glucose, cholesterol and cholesterol HDL levels in diabetes, Centr. Africa J. Med. 29, 80–82 (1983).
O. B. Martinez, A. C. MacDonald, R. Gibson, et al., Dietary chromium and effect of chromium supplementation on glucose tolerance of elderly Canadian women, Nutr. Res. 5, 609–620 (1985).
M. B. Rabinowitz, H. C. Gonick, S. R. Levin, et al., Clinical trial of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men, Biol. Trace Element Res. 5, 449–466 (1983).
M. I. J. Uusitupa, J. T. Kumpulainen, E. Voutilainen, et al., Effect of inorganic chromium supplementation on glucose tolerance, insulin response, and serum lipids in noninsulin-dependent diabetes, Am. J. Clin. Nutr. 38, 404–410 (1983).
P. M. Clarkson, Nutritional erogogenic aids: chromium, exercise, and muscle mass, Int. J. Sport Nutr. 1, 289–293 (1991).
R. J. Moore and K. E. Friedl, Ergogenic aids: physiology of nutritional supplements: chromium picolinate and vanadyl sulfate, Natl. Strength Conditioning Assoc. J. 14, 47–51 (1992).
R. G. Lefavi, R. A. Anderson, R. E. Keith, et al., Efficacy of chromium supplementation in athletes: emphasis on anabolism, Int. J. Sport Nutr. 2, 111–122 (1992).
D. Whitmire, Vitamins and minerals: a perspective in physical performance, in Sports Nutrition for the 90s, J. R. Berning and S. N. Steen, eds., Aspen, Gaithersburg, MD, pp. 129–151 (1991).
A. S. Abraham, B. A. Brooks, and U. Eylath, The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes, Metabolism 41, 768–771 (1992).
N. A. Lee and C. A. Reasner, Beneficial effect of chromium supplementation on serum triglycerides levels in NIDDM, Diabetes Care 17, 1449–1452 (1994).
V. L. K. Thomas and S. S. Gropper, Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors, Biol. Trace Element Res. 55, 297–305 (1997).
B. Bahadori, W. Sandra, C. Hacker, et al., Effects of chromium picolinate on insulin levels and glucose control in obese patients with type-II diabetes mellitus, Diabetes 48(Suppl. 1), A349 (1999).
R. A. Anderson, N. C. Cheng, N. A. Bryden, et al., Elevated levels of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes, Diabetes 46, 1786–1791 (1997).
M. K. Hellerstein, Is chromium supplementation effective in managing type II diabetes? Nutr. Rev. 56, 302–306 (1998).
N. Cheng, X. Zhu, H. Shi, et al., Follow-up survey of people in China with type 2 diabetes mellitus consuming supplemental chromium, J. Trace Elements Exp. Med. 12, 55–60 (1999).
A. Ravina and L. Slezack, Chromium in the treatment of clinical diabetes mellitus, Harefuah 125, 142–145 (1993).
A. Ravina, L. Slezak, A. Rubal, et al., Clinical use of the trace element chromium(III) in the treatment of diabetes mellitus, J. Trace Elements Exp. Med. 8, 183–190 (1995).
R. A. Anderson, A.-M. Roussel, N. Zouari, et al., Potential antioxidant effects of zinc and chromium supplementation of people with type 2 diabetes mellitus, J. Am. Coll. Nutr. 20, 212–218 (2001).
L. G. Trow, J. Lewis, R. H. Greenwood, et al., Lack of effect of chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes, Int. J. Vitam. Nutr. Res. 70, 14–18 (2000).
B. M. Morris, S. Kouta, R. Robinson, et al., Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus, Diabetic Med. 17, 684–686 (2000).
H. Rabinovitz, A. Leibovitz, Z. Madar, et al., Blood glucose and lipid levels following chromium supplementation in diabetic elderly patients on a rehabilitation program, Gerontologist 40(S), 38 (2000).
D. Ghosh, B. Bhattacharya, B. Mukherjee, et al., Role of chromium supplementation in Indians with type 2 diabetes mellitus, J. Nutr. Biochem. 13, 690–697 (2002).
S. M. Bahijri, S. M. Mira, A. M. Mufti, et al., The effects of inorganic chromium and brewer’s yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes, Saudi Med. J. 21, 831–837 (2000).
S. M. A. Bahijri and A. M. B. Mufti, Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status, Biol. Trace Element Res. 85, 97–109 (2002).
Y. Sun, K. Mallya, J. Ramirez, et al., The biomimetic [Cr3O(O2CCH2CH3)6(H2O3]+ decreases cholesterol and triglycerides in rats: towards chromium-containing therapeutics, J. Biol. Inorg. Chem. 4, 838–845 (1999).
Y. Sun, B. J. Clodfelder, A. A. Shute, et al., The biomimetic [Cr3O(O2CCH2CH3)6(H2O3]+ decreases plasma insulin, cholesterol and triglycerides in healthy and type II diabetic rats but not type I diabetic rats, J. Biol. Inorg. Chem. 7, 852–862 (2002).
W. T. Cefalu, Z. Q. Wang, X. H. Zhang, et al., Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats, J. Nutr. 132, 1107–1114 (2002).
L. Jovanovic, M. Gutierrez, and C. M. Peterson, Chromium supplementation for women with gestational diabetes mellitus, J. Trace Elements Exp. Med. 12, 91–97 (1999).
A. Ravina, L. Slezak, N. Mirsky, et al., Control of steroid-induced diabetes with supplemental chromium, J. Trace Elements Med. Biol. 12, 375–378 (1999).
A. Ravina, L. Slezak, N. Mirsky, et al., Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium, Diabetic Med. 16, 164–167 (1999).
D.-S. Kim, T.-W. Kim, I.-K. Park, et al., Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body weight in dexamethasone-treated rats, Metabolism 51, 589–594 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vincent, J.B. Recent developments in the biochemistry of chromium(III). Biol Trace Elem Res 99, 1–16 (2004). https://doi.org/10.1385/BTER:99:1-3:001
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/BTER:99:1-3:001